EIF4G1 and neoplasm: Analysis of the samples obtained showed a reduction in eIF4E:eIF4G1 interaction among tumours treated with SBI-756 as a single agent or in combination with venetoclax, compared to vehicle or venetoclax alone (Fig. 3c, d).